A Blinded, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 757456 Administered Subcutaneously to Healthy Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 May 2018
At a glance
- Drugs IONIS AGT LRx (Primary) ; Spironolactone
- Indications Hypertension
- Focus Adverse reactions
- Sponsors Ionis Pharmaceuticals
- 01 May 2018 Planned End Date changed from 31 Jan 2019 to 31 Aug 2018.
- 01 May 2018 Planned primary completion date changed from 1 Nov 2018 to 30 May 2018.
- 01 May 2018 Status changed from recruiting to active, no longer recruiting.